Short answer
TuHURA Biosciences, Inc./NV (HURA) filed its fiscal 2024 10-K annual report with the SEC on Mar 31, 2025. It reported revenue of $0 and net income of −$22M.
- Top risk flagged: FDA partial clinical hold on Phase 3 IFx-2.0 trial to be lifted by Q2 2025 per agreement, critical to initiation of pivotal registration study
FY2024 key financial metrics · XBRL
- Revenue
- $0
- Net income
- −$22M
- +26.0% YoY
- EPS (diluted)
- −$1.21
- +51.0% YoY
- ROE
- -148.6%
- −2029.4 pp YoY
- Operating cash flow
- −$15M
- −23.2% YoY
Source: XBRL data from the TuHURA Biosciences, Inc./NV (HURA) FY2024 10-K on SEC EDGAR. USD.
TuHURA Biosciences, Inc./NV FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business: Clinical-stage immuno-oncology focused on innate immune agonists and tumor microenvironment modulators to overcome resistance to checkpoint inhibitors
- New emphasis: Acquisition of Kineta, Inc. to incorporate anti-VISTA antibody checkpoint inhibitor targeting acquired resistance
- Strategic shift: Reverse merger and rebranding to TuHURA Biosciences; expansion into bi-functional ADCs/APCs targeting Delta Opioid Receptor on MDSCs
- Quantitative metric: Planned Phase 3 trial for IFx-2.0 targeting Merkel cell carcinoma with FDA accelerated approval pathway, Phase 3 start possible Q2 2025
- Noteworthy fact: Unique bi-specific antibody-peptide conjugates using Delta Opioid Receptor technology represent a novel approach to modulate tumor microenvironment immunosuppression
Management Discussion & Analysis
- No information on cash flow, buybacks, dividends, or capital expenditures
- Management highlights risk and uncertainty in business environment with no specific outlook or guidance
- Forward-looking statements qualified with caution, no numerical forecasts provided
Risk Factors
- FDA partial clinical hold on Phase 3 IFx-2.0 trial to be lifted by Q2 2025 per agreement, critical to initiation of pivotal registration study
- Direct exposure to regulatory milestones in Kintara Merger earnout: enrollment of 10 metastatic breast cancer patients plus 8 weeks follow-up by Dec 31, 2025
- Heavy dependence on third-party CROs and manufacturers for clinical trials and product supply for IFx-2.0 and KVA12123 antibody programs
- Competitive threat from established checkpoint inhibitor Keytruda® (Merck), partnered product in Phase 3 trial, and emerging anti-VISTA asset KVA12123 via Kineta acquisition
- High leverage from $31.3M convertible notes at 20% interest converted into equity in 2024, with only $12.7M cash on hand at year-end, raising near-term liquidity risk
Generated from the filing text; verify against the original. How to read a 10-K
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.